LGE-MRI for diagnosis of left atrial cardiomyopathy as identified in high-definition endocardial voltage and conduction velocity mapping

Deborah Nairn, MSc^{1*#}, Martin Eichenlaub, MD^{2#}, Björn Müller-Edenborn, MD², Heiko Lehrmann, MD², Claudia Nagel, MSc¹, Luca Azzolin, PhD¹, Giorgio Luongo, PhD¹, Rosa M. Figueras Ventura, PhD³, Barbara Rubio Forcada, MSc³, Anna Vallès Colomer, MSc³, Thomas Arentz, MD², Olaf Dössel, PhD¹, Axel Loewe, PhD^{1§} and Amir Jadidi, MD^{2§}

¹*Institute of Biomedical Engineering, Karlsruhe Institute of Technology, Karlsruhe, Germany*

²*Department of Electrophysiology, University-Heart-Center Freiburg-Bad Krozingen, Bad Krozingen, Germany*

³*Adas 3D Medical SL, Carrer Paris 179, Barcelona, Spain*

^{#, §} *These authors contributed equally.*

Short title: LGE-MRI for diagnosis of left atrial cardiomyopathy

Address for correspondence: Deborah Nairn, MSc, Fritz-Haber-Weg 1, 76131 Karlsruhe, Germany, publications@ibt.kit.edu

Conflict of Interest Statement: RF, BF and AC are employees of Adas 3D Medical. This investigator-initiated study was financially supported by Medtronic. Medtronic had no influence on collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

Word count: 4999

Abstract

Background: Electro-anatomical voltage, conduction velocity (CV) mapping and late-gadolinium-enhancement-magnetic-resonance-imaging (LGE-MRI) are different diagnostic modalities for atrial cardiomyopathy (ACM). However, discrepancies remain in the location and extent of detected ACM.

Objectives: (1) Comparison of ACM extent and location between current modal-

ities. (2) Development of new estimated optimised image-intensity-thresholds (EOIIT) for LGE-MRI identifying patients with ACM.

Methods: Thirty-six ablation-naïve persistent AF patients underwent LGE-MRI and high-definition electro-anatomical mapping in sinus rhythm. Significant ACM was defined as low-voltage-substrate (LVS) extent $\geq 5\%$ of the left atrium (LA) surface at <0.5 mV. LGE areas were classified using the Utah, image-intensity-ratio (IIR >1.20) and new EOIIT method for comparison to LVS and slow-conduction-areas <0.2 m/s. ROC-analysis determined the LGE-extent enabling accurate diagnosis of ACM.

Results: The degree and distribution of detected pathological substrate varied significantly ($p < 0.001$) across the mapping modalities: 3% (IQR 0-12%) of the LA displayed LVS <0.5 mV vs. 14% (3-25%) slow-conduction-areas <0.2 m/s vs. 16% (6-32%) LGE with Utah method vs. 17% (11-24%) using IIR >1.20 , with enhanced discrepancies on posterior LA. A linear correlation was found between the OIIT and each patient's mean blood pool intensity ($R^2 = 0.89$, $p < 0.001$). LGE-MRI-based ACM-diagnosis improved with the novel EOIIT (83% sensitivity, 88% specificity, AUC:0.94) in comparison to the Utah method (60% sensitivity, 75% specificity, AUC:0.76), and IIR >1.20 (58% sensitivity, 75% specificity, AUC:0.71)

Conclusion: Important discordances in distribution of pathological substrate exist between LA-LVS, CV and LGE-MRI, irrespective of the LGE-detection protocol that is used. However, the new EOIIT method improves LGE-MRI-based ACM-diagnosis in ablation-naïve AF-patients.

Key Words: Atrial fibrillation, LGE-MRI, Electro-anatomical mapping, Conduction velocity, Pathological substrate.

1. Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia causing an irregular heart rhythm, associated with increased risk for stroke and heart failure [1]. Pulmonary vein isolation (PVI) is a commonly used treatment for AF with a high success rate (75-90%) in paroxysmal AF patients [2]. However, persistent AF patients may present an atrial cardiomyopathy (ACM) with extra-PV pathological substrate, which contributes to the maintenance of AF and reduces the success rate markedly [3, 4].

Electro-anatomical mapping (EAM) during sinus rhythm (SR) identifying low voltage bipolar electrograms (<0.5 mV) is a common technique used to locate pathological substrate [5, 6]. Recently, conduction velocity (CV) mapping has also been investigated due to the structural and functional abnormalities resulting in conduction slowing in the context of AF-associated ACM [7, 8, 9]. Another commonly used method is late gadolinium enhancement magnetic resonance imaging (LGE-MRI) [10, 11, 12]. The advantage of LGE-MRI is that it is a non-invasive diagnostic method. However, the spatial resolution of LGE-MRI is limited. Although all the above-mentioned methods detect pathological substrate, discordances in their location and extent have been reported when mapping during AF [13].

This study assessed the spatial distribution of pathological left atrial substrate as detected in LGE-MRI (using various MRI post-processing methods), voltage and CV mapping during sinus rhythm (SR) in ablation-naïve AF patients. The mapping modalities were compared to one another. Additionally, a new estimated optimised image-intensity-thresholding method (EOIIT) for LGE-MRI was developed, enabling identification of patients with atrial cardiomyopathy (ACM) as

26 diagnosed by low-voltage areas at <0.5 mV in SR.

27 **2. Methods**

28 *2.1. Electro-anatomical mapping (EAM)*

29 High-density ($>1,200$ mapped sites per left atrium (LA)) activation and volt-
30 age mapping was performed using a 20-polar Lasso-Nav mapping catheter or a
31 PentaRay catheter (electrode size: 1 mm, spacing: 2–6–2 mm). Mapping was
32 conducted while the patient was in SR prior to PVI using the CARTO-3 mapping
33 system (Biosense Webster, Diamond Bar, CA, USA). Further details about the
34 signal processing and calculation of the LAT, voltage and CV can be found in the
35 supplementary material section 1.1.

36 In two series of analyses, cut-off values of <0.5 and <1.0 mV were applied
37 to the bipolar voltage maps to define the low voltage substrate (LVS) [14, 15].
38 Additionally, a CV cut-off value was set at 0.2 m/s to indicate pathological slow
39 conducting substrate [16].

40 *2.2. Late gadolinium enhancement magnetic resonance imaging (LGE-MRI)*

41 LGE-MRI was performed on a 3 T scanner (Somatom Skyra, Siemens Health-
42 care, Erlangen, Germany) as described previously [10, 11]. In brief, LGE-MRI
43 was acquired 15 minutes after contrast injection with a dose of 0.1 mmol Gado-
44 teridol per kg body weight (ProHance®, Bracco, Milan, Italy). Voxel size was
45 $1.25 \times 1.25 \times 2.5$ mm (reconstructed to $0.625 \times 0.625 \times 1.25$ mm), repetition time was
46 3.1 ms, echo time was 1.4 ms and flip angle was 14° .

47 Two independent expert core laboratories performed the LA segmentation and
48 detection of LGE-areas: Merisight (Marrek Inc., Sandy, Utah, USA) for the Utah

49 method and the Adas group (Adas3D Medical SL, Barcelona, Spain) for the
50 "image-intensity-ratio (IIR)" method by Benito et al. [12]. All image analysts
51 were blinded to any clinical data. Further details about the two methods can be
52 found in the supplementary material section 1.2.

53 2.3. Analysis

54 2.3.1. LA mean geometry and statistical analysis of pathological substrate

55 For this study, geometries obtained from each modality for all patients were
56 aligned to a mean LA shape. Thus, a direct comparison between the EAM and
57 LGE-MRI and between patients could be performed without variations caused
58 by spatial displacement. The steps behind this approach are introduced in the
59 supplementary material, section 1.2 and figure S1. Information on the pulmonary
60 veins (PVs) and mitral valve (MV) were excluded from all substrate analyses.

61 The median value for each point on the geometry across all patients was cal-
62 culated for the voltage, CV and MRI maps (image-intensity values), providing a
63 visual comparison between mapping modalities without the influence of outliers
64 due to patient-specific differences.

65 A spatial histogram for each mapping modality was created to assess which
66 areas most commonly exhibit pathological substrate. Providing for the first time
67 a spatial histogram of LVS and slow conduction areas and a comparison of LGE-
68 MRI spatial histograms with the one previously reported by Higuchi et al. [17].

69 Additionally, a correlation analysis was performed between each pair of map-
70 ping modalities identifying the difference in pathological substrate extent for each
71 patient.

72 2.3.2. *Detection of LA LGE-areas based on estimated optimised image intensity*
73 *thresholding method "EOIIT"*

74 For this analysis, the individual patient's "optimised image-intensity-threshold"
75 was considered as the threshold with best quantitative match between LGE-extent
76 and LVS-extent (<0.5 mV) and plotted against the mean bloodpool value of the
77 LA-LGE-MRI for each patient. A linear correlation was calculated using a leave-
78 one-out cross-validation method to determine the EOIIT method for the entire
79 cohort. This analysis was performed for the (1) entire LA, (2) anterior LA and (3)
80 posterior LA. Details on this semi-automatic segmentation approach are given in
81 the supplementary material section 1.3.

82 The performance of the new thresholds were then evaluated by examining the
83 relationship between the LVS-extent (<0.5 mV) and LGE-MRI substrate for each
84 MRI post-processing method (Utah, $IIR > 1.20$ and EOIIT). Patients with a LVS-
85 extent ≥ 5 cm² of LA surface corresponding to a LVS-extent of $\geq 5\%$ at <0.5 mV
86 were classified as having substantial extent of LVS [18].

87 Receiver operating curves were created for the $IIR > 1.2$ method and the EOIIT
88 method for the entire LA, anterior and posterior. In this way, the most sensitive
89 and specific LGE-extent was determined to detect significant LA-LVS. A fibrotic
90 tissue extent $\geq 20\%$ of the total LA-wall (Utah-stages III and IV) was classified as
91 relevant LGE for the Utah method [19].

92 **3. Results**

93 3.1. *Patient characteristics*

94 Thirty-six patients with persistent AF (66 ± 9 years old, 84% male) underwent
95 EAM and LGE-MRI prior to PVI. All patients were electrically cardioverted

96 4-6 weeks prior to PVI. Fourteen (39%) patients with AF recurrence were car-
97 dioverted again on admission. The institutional review board approved the study
98 and all patients provided written informed consent prior to enrollment. The sup-
99plementary material provides details of the patients' characteristics (Table S1) and
100 EAM and LGE-MRI data (Table S2).

101 *3.2. Spatial distribution of left atrial pathological substrate in electro-anatomical* 102 *voltage-activation mapping versus LGE-MRI*

103 Figure 1 reveals discrepancies in the distribution and extent of pathological
104 substrate between EAM modalities and LGE-MRI. Both LGE-MRI methods iden-
105 tified extensive pathological substrate on the inferior wall, whereas the electro-
106 grams in this area (marked with a square) are non-fractionated signals with high
107 amplitudes. In contrast, low amplitude signals are seen (marked with a circle)
108 where LVS and slow CV were identified. All patient-specific substrate maps are
109 shown in the supplementary material figure S2.

110 *3.3. Spatial distribution of left atrial pathological substrate as identified by me-* 111 *diان voltage values, conduction velocity and LGE-MRI intensity*

112 Figure 2 reveals notable differences in the median voltages between the an-
113 terior (median 1.22 mV, IQR 1.05-1.46 mV) and posterior wall (median 1.58 mV,
114 IQR 1.34-1.90 mV). The CV shows similar differences although less pronounced
115 (anterior: median 0.27 m/s, IQR 0.25-0.29 m/s and posterior: median 0.33 m/s,
116 IQR 0.31-0.35 m/s). On the other hand, the LGE-MRI IIR method reveal rela-
117 tively little difference between the anterior and posterior wall, with median IIR
118 values 0.98 (IQ3 0.96-1.11) and 0.99 (IQ3 0.90-1.12), respectively, signifying
119 more pathologically enhanced tissue at posterior LA.

Figure 1: **Three-dimensional distribution of voltage <0.5 mV, CV <0.2 m/s and LGE-areas detected with IIR 1.2-1.32 and the Utah method in a representative patient.** The top and middle row show the EAM and LGE-MRI information on the patient's geometry and the mean shape, respectively. The bottom row shows a binary classification, where pathological substrate is shown in red and healthy tissue in cream. Each geometric shape represents a point on the map where the corresponding electrogram is shown in the middle column.

3.4. Spatial localisation frequency of atrial sites displaying pathological substrate

Figure 3 shows that the highest probability for LGE-MRI areas was found around the left inferior PV (with the UTAH method median 56% and IIR >1.20 44% of the patients). In contrast, the LVS <0.5 mV spatial histogram rarely (8% of patients) indicated pathological substrate on posterior wall. Evaluating LVS <1 mV and CV <0.2 mV, the percentage of patients with pathological substrate

Figure 2: **Spatial distribution of the pathological substrate as detected by the different mapping modalities.** Each column shows the median values of total study cohort on a representative LA geometry of the mapping modality mentioned at the head of the column.

for both methods was 28% adjacent to the left inferior PV. All methods identified a similar percentage of patients with pathological substrate on the anterior wall (22% LVS <0.5 mV, 22% IIR>1.2, 25% UTAH, 31% CV< 0.2 m/s, 42% LVS < 1 mV).

Figure 3: **Spatial histogram of left atrial pathological substrate.** The colour indicates the percentage of patients for which the respective method identified pathological substrate at the specific location. Each column shows the spatial histogram of the mapping modality mentioned at the top.

131 *3.5. Quantification of left atrial pathological substrate.*

132 Figure 4 reveals that the lowest difference in terms of global pathological LA
133 substrate extent was found for LVS <0.5 mV and CV <0.2 m/s (median difference
134 6%) and LGE-extent assessed with IIR >1.2 and UTAH (11%). When comparing
135 LVS <0.5 mV and the LGE-extent with UTAH method, the difference of globally
136 detected substrate was relatively low (median difference 10% of the LA surface;
137 range from 0 to 25%). While both methods detected a similar total extent of
138 pathological LA substrate, the location of detected substrate differed importantly
139 between the methods (see supplementary material figure S2).

140 *3.6. Optimising the LGE-MRI threshold to identify low-voltage substrate*

141 The "optimised-image-intensity-threshold" (with best match in LGE-extent
142 and LVS-extent in an individual patient) was reported to each patient's left atrial
143 mean bloodpool intensity value (figure 5). Separate analyses were performed on
144 the anterior and posterior LA regions to counter the clear distinction between the
145 two mapping modalities on the posterior wall. For the entire LA, anterior and
146 posterior wall, the linear relationship can be described as $y = 0.97x + 86$ ($R^2 =$
147 0.88), $y = 0.96x + 72$ ($R^2 = 0.89$) and $y = 0.93x + 85$ ($R^2 = 0.86$), respectively,
148 corresponding to the estimated optimised-image-intensity-threshold (EOIIT). De-
149 pending on the individual patient's mean bloodpool intensity value, the EOIIT-
150 value can be determined using the linear correlation, improving the concordance
151 between LGE-extent and LVS-extent (figure 6CD).

152 Supplementary material figure S3 demonstrates the distribution extent of LVS
153 and LGE-areas (for the entire LA, anterior and posterior LA) for both the IIR>1.2
154 and the new EOIIT method for all patients. Analysis of EOIIT-based LGE-extent
155 revealed similarities with LVS-extent (figure 6A and B) with good correlation on

Figure 4: **Violin plot demonstrating the extent of pathological substrate (as percentage of LA surface area) for different mapping modalities and the difference of detected substrate between the methods.** Top row shows the extent for each mapping modality defined on the x-axis. Bottom row shows the difference in extent of detected substrate for the method on the x-axis with the one identified by the colour of the violin plot as reference. Each dot inside a violin plot represents the value for one patient, the white dot represents the median and the bar shows the interquartile range.

Figure 5: **Identification of the EOIIT using linear correlation between the individual patient's mean bloodpool intensity (x-axis) and optimal image-intensity-threshold (y-axis).** From left to right, the results for the entire left atria, anterior wall and posterior wall are shown. Each blue dot represents one patient and the black line is the best linear fit.

the anterior wall ($r=0.68$, figure 6C). Supplementary material section 2.4 provides more information on the performance of the new EOIIT compared to voltage on the posterior wall, the entire atrium and CV mapping. Detection of LA-LGE-areas using the new EOIIT-method still did not provide an exact match to LVS-extent in every patient. This is due to the OIIT-value of each patient not lying precisely on the EOIIT-line (figure 5). As seen in figure 6, EOIIT-based LGE-extent (42%) is similar to LVS-extent <0.5 mV (55%) in patient 35. However, the locations of detected substrate remain different between voltage mapping and LGE-MRI.

3.7. *Estimated optimised image intensity threshold (EOIIT) enables LGE-MRI-based diagnosis of patients with atrial cardiomyopathy presenting low-voltage substrate*

Despite difficulties in exact quantitative match between EOIIT-based LGE-extent and LVS-extent, we hypothesized that the new EOIIT-method could be useful to diagnose patients with significant ACM (defined as LVS <0.5 mV at $>5\%$

Figure 6: (A) Spatial histogram of each mapping modality including the new EOIT method. (B) violin plot showing the pathological substrate extent for different mapping modalities and the difference between them and the new EOIT method. (C) Percentage of substrate extent of each LGE-MRI method versus LVS-extent for the anterior LA-wall. (D) Distribution extent of LVS and LGE-areas for the anterior LA in patient 35.

170 of LA surface area). ROC-analysis determined the best quantitative LGE-extent
 171 for ACM-diagnosis (figure 7). ACM-diagnosis was most accurate when using the

EOIIT-based LGE-extent >13% at the anterior LA (sensitivity: 83%, specificity: 88%, AUC: 0.94), compared to IIR >1.20-based LGE-extent $\geq$ 31% (sensitivity: 58%, specificity: 75%, AUC: 0.71). Figure 8 additionally illustrates these results, where the mid panel dashed line corresponds to >13% EOIIT-based LGE-extent and >31% IIR >1.20-based LGE-extent at the anterior LA. For the entire LA, the EOIIT-based (>4%) and Utah-based ($\geq$ 20%) LGE-extent had a sensitivity and specificity of 75% and 67% (AUC: 0.65) and 60% and 75% (AUC: 0.76), respectively.

Figure 7: ROC analysis determines the diagnostic LGE-extent that identifies patients with ACM (defined as LVS <0.5 mV at $\geq$ 5% of total LA surface. From left to right: results for identification of $\geq$ 5% LVS-extent on the entire atria when using LGE-extent from the entire LA, anterior and posterior wall. Yellow and red lines show the ROC of the EOIIT-based and IIR >1.2-based methods for LGE-detection, respectively.

4. Discussion

4.1. Main findings

This study investigated the similarity of different mapping modalities in detecting left atrial pathological substrate. Three key findings can be reported:

Figure 8: Violin plots illustrate the extent of detected LA substrate compared to pathological low-voltage substrate<0.5 mV at ≥5% of total LA surface. The results for the entire LA, anterior wall and posterior wall are shown from the left to right. The blue violins illustrate the extent of pathological substrate in patients who had significant low-voltage extent ≥5%. The purple violins illustrate the extent of pathological substrate in patients who had no significant low-voltage substrate (low-voltage extent <5%).

1. Important discordances exist in the extent and spatial localisation of identified pathological left atrial substrate when comparing electro-anatomical voltage and conduction velocity mapping to LGE-MRI. These discordances exist with all LGE-detection protocols and are more pronounced on the posterior LA wall.
2. The extent of left atrial slow-conduction-areas (CV<0.2 m/s) correlated moderately ($r = 0.57$) well to LVS (LVS<0.5 mV).
3. Applying the new EOIT-method on the anterior LA-wall enables LGE-MRI-based diagnosis of AF patients with ACM (presenting significant low voltage substrate<0.5 mV at ≥5% LA surface) with a sensitivity of 83% and a specificity of 88%. However, significant differences in localisation of LGE-areas to LVS still remain.

196 4.2. *Clinical significance of left atrial cardiomyopathy in patients with atrial fib-*
197 *rillation*

198 Several studies have demonstrated the relevance of LA-LVS<0.5mV regard-
199 ing increased arrhythmia recurrences within 12 months following pulmonary vein
200 isolation (PVI) for AF [14, 20]. Recently, the predictive value of LVS<0.5mV
201 at >5% of LA surface was demonstrated with regard to arrhythmia recurrence
202 rate following PVI. [18]. Therefore, this LVS-extent was used in the current
203 study. In addition, the presence of ACM, as assessed by LA-LVS is associated
204 with an increased risk for ischemic stroke [21]. Therefore, the most recent Eu-
205 ropean guidelines on the management of patients with AF recommend diagnosis
206 of ACM in order to initiate therapeutic efforts in limiting progression and related
207 complications of ACM [1].

208 4.3. *Regional differences in detected left atrial substrate - comparing EAM to*
209 *LGE-MRI*

210 Pathological substrate was most consistently (20-40% of patients) found with
211 all modalities (low-voltage, slow conduction and LGE-MRI) at the anterior LA-
212 wall, confirming preferential profibrotic remodeling in this area. Across the whole
213 LA, the CV was 0.48 ± 0.39 m/s, which is comparable to previous findings in AF
214 patients [8, 9]. Our study confirms that low-voltage and slow-conduction areas
215 most frequently develop on the anteroseptal LA-wall and roof [22, 23].

216 In contrast, both the Utah- and IIR>1.20 methods most frequently detect LGE
217 at the left posterior LA adjacent to the descending aorta, which is consistent with
218 previous reports [17, 24, 13]. Caixal et al. demonstrated that the spatial proximity
219 of posterior LA-wall to the descending aorta determines the degree of LGE in this
220 region [24]. In a subset of 16 patients, these authors reported reduction of bipolar

221 voltages and CV values in LGE-areas at left posterior LA. In the current study,
222 56% (Utah-method) and 44% (IIR>1.20-method) of patients presented LGE at
223 posterior-LA adjacent to the left PV, whereas CV<0.2 m/s was found in 28% and
224 LVS<0.5mV in 8% of patients. Although, voltage reduction can be observed
225 in some patients within this LA-area, the electrograms are non-fractionated, and
226 display voltages>1.0 mV in >70% of patients. Thus discrepancies in substrate
227 qualification remain, even when defining LVS as <1.0 mV or <1.5 mV (figure 3).
228 The current study demonstrates that extent and location of LGE-areas differ im-
229 portantly from LA-LVS<0.5 mV.

230 *4.4. Complementarity of mapping systems*

231 Pathological substrate is frequently in opposite locations when comparing
232 electrophysiological substrate to LGE-areas. When considering all patients (sup-
233plementary material figures S2-S3), the distribution and location of the patholog-
234ical substrate is well correlated in some, while they differ in others.

235 One could hypothesise that the mapping modalities provide complementary
236 information that could be leveraged when determining ablation targets. It has
237 been reported that different fibrotic patterns of various types and densities exist,
238 which could affect the mapping modalities differently [25]. Small patchy fibrotic
239 strands with small contributions to the signal may be compensated by surrounding
240 myocytes and atrial far-fields, causing "undersensing" of fibrotic areas. Addition-
241ally, endocardial mapping measurements are dominated by the first 1-2 mm en-
242docardial layer substrate. Fibrosis solely expressed on the epicardial side may be
243 hidden to endocardial catheters. Examining all three methods (CV, LVS and LGE-
244MRI) may help to comprehensively assess the pathological LA substrate with a
245 more localised analysis than possible with the ECG [26, 27]. However, the fact

246 that ablation of LGE-areas in the DECAAF II study did not improve sinus rhythm
247 maintenance rates, indicates that the detected LGE-areas (using the Utah-method)
248 may not have a major arrhythmogenic role in human AF [19].

249 4.5. *Optimising LGE-MRI thresholds*

250 Identifying the same regions of pathological substrate across all established
251 mapping modalities was not possible with the current techniques. Therefore, we
252 sought to improve LGE-based detection of total LA LVS-extent, thus allowing a
253 more accurate ACM-diagnosis. In this analysis, new LGE-MRI thresholds were
254 identified, which, similarly to the IIR method, can be determined using each pa-
255 tient's mean bloodpool intensity.

256 Benito et al. studied 30 patients with various stages of AF. They set the thresh-
257 old to determine pathological substrate at >1.20 [12]. As discussed, determining
258 the exact extent of pathological substrate on the thin posterior wall remains chal-
259 lenging, which may be related to MRI resolution [28]. Since the high-intensity
260 areas were mostly located on the posterior wall across the patient cohort, taking
261 the mean tissue IIR + 2 SD as the threshold in the study by Benito et al. was po-
262 tentially influenced by these high-intensity areas on the posterior wall. Therefore,
263 their suggested threshold might be too high to identify pathological substrate on
264 the anterior wall.

265 The new EOIT-based thresholds presented in this work, however, can pro-
266 vide a better estimate of the LVS-extent located on the anterior LA-wall, thus
267 enabling the diagnosis of ACM in individuals. Previous studies revealed that
268 LVS first develops on the anterior LA, and in later stages involves the posterior
269 LA-wall. [22, 23] Therefore, diagnosis of ACM that is based on analysis of LGE-
270 presence on the anterior LA-wall is both sensitive and specific for ACM-diagnosis,

271 as shown in our study. Accurate diagnosis of ACM provides a deeper insight into
272 whether PVI-only would be sufficient or if additional LA mapping is needed.

273 **5. Limitations**

274 The CV calculation method in the current study did not exclude uncertain
275 LAT values coming from fractionated multicomponent electrograms, potentially
276 limiting the accuracy of CV-maps. LGE-MRI is limited in its spatial resolution (1-
277 2mm) and cardiac and respiratory motions and adjacent enhanced vascular struc-
278 tures (eg aorta) may produce partial volume effect, resulting in "false" LA-LGE-
279 sites and a lack of spatial correlation between LGE-areas and LVS. Additionally,
280 the patient cohort size for this study was relatively small. Thus, overfitting may
281 play a role when computing the linear fit to determine the new LGE-MRI thresh-
282 olds. To compensate for this effect, leave-one-out-cross validation was used to ob-
283 tain the best fit. The new EOIT-LGE-MRI-based ACM-diagnosis needs further
284 validation in larger external cohorts, assessing its predictive value for arrhythmia
285 recurrence following PVI for persistent AF. Furthermore, adaptations for determi-
286 nation of lab-specific EOIT-curves may be necessary due to the fact that LGE-
287 detection depends on multiple factors (e.g. type, dosage and timing of contrast
288 injection, magnetic field strength, acquisition protocol).

289 **6. Conclusion**

290 Important discordances exist in localisation of detected pathological LA-LVS
291 vs. slow conduction vs. LGE-areas in MRI. Despite a good correlation between
292 the extent of LA-LVS and EOIT-LGE-areas, the exact locations of identified

293 pathological substrate differ. The new EOIT-method enables more accurate LGE-
294 MRI-based ACM diagnosis in ablation-naive AF-patients.

295 **7. Author Approval**

296 All authors critically revised the manuscript and approved the final submitted
297 manuscript.

298 **8. Data Availability**

299 For data privacy reasons, the raw data used for this study cannot be published.
300 The figures within the article and supplementary material show detailed analyses
301 for all patients used. Requests to access these datasets should be directed to:
302 Deborah Nairn, deborah.nairn@kit.edu.

303 **Acknowledgements**

304 We gratefully acknowledge financial support by Deutsche Forschungsgemein-
305 schaft (DFG) through DO637/22-3, by the Ministerium für Wissenschaft, Forschung
306 und Kunst Baden-Württemberg through the Research Seed Capital (RiSC) pro-
307 gram and by Medtronic.

308 **References**

- 309 [1] G. Hindricks, T. Potpara, N. Dagres, et al., 2020 ESC guidelines for the diag-
310 nosis and management of atrial fibrillation developed in collaboration with
311 the European Association for Cardio-Thoracic Surgery (EACTS), European
312 Heart Journal 42 (5) (2021) 373–498. doi:10.1093/eurheartj/ehaa612.

- 313 [2] P. Taghji, M. El Haddad, T. Phlips, et al., Evaluation of a strategy aiming to
314 enclose the pulmonary veins with contiguous and optimized radiofrequency
315 lesions in paroxysmal atrial fibrillation: A pilot study., *JACC: Clinical Elec-*
316 *trophysiology* 4 (1) (2018) 99–108. doi:10.1016/j.jacep.2017.06.023.
- 317 [3] A. Verma, C. Jiang, T. R. Betts, et al., Approaches to catheter ablation for
318 persistent atrial fibrillation., *The New England Journal of Medicine* 372 (19)
319 (2015) 1812–22. doi:10.1056/NEJMoa1408288.
- 320 [4] A. Goette, J. M. Kalman, L. Aguinaga, et al.,
321 EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomy-
322 opathies: Definition, characterization, and clinical implication., *Heart*
323 *rhythm* 14 (1) (2017) e3–e40. doi:10.1016/j.hrthm.2016.05.028.
- 324 [5] A. Jadidi, M. Nothstein, J. Chen, et al., Specific electrogram characteris-
325 tics identify the extra-pulmonary vein arrhythmogenic sources of persistent
326 atrial fibrillation - characterization of the arrhythmogenic electrogram pat-
327 terns during atrial fibrillation and sinus rhythm., *Scientific Reports* 10 (1)
328 (2020) 9147. doi:10.1038/s41598-020-65564-2.
- 329 [6] J. Seitz, C. Bars, G. Théodore, et al., AF ablation guided by spatiotemporal
330 electrogram dispersion without pulmonary vein isolation: A wholly patient-
331 tailored approach., *Journal of the American College of Cardiology* 69 (3)
332 (2017) 303–321. doi:10.1016/j.jacc.2016.10.065.
- 333 [7] R. Morgan, M. A. Colman, H. Chubb, et al., Slow conduction in the border
334 zones of patchy fibrosis stabilizes the drivers for atrial fibrillation: Insights

- 335 from multi-scale human atrial modeling., *Frontiers in physiology* 7 (2016)
336 474. doi:10.3389/fphys.2016.00474.
- 337 [8] Y. Zheng, Y. Xia, J. Carlson, et al., Atrial average conduction velocity in
338 patients with and without paroxysmal atrial fibrillation, *Clinical Physiology*
339 and Functional Imaging doi:10.1111/cpf.12342.
- 340 [9] B. Verma, T. Oesterlein, A. Loewe, et al., Regional conduction
341 velocity calculation from clinical multichannel electrograms in hu-
342 man atria, *Computers in Biology and Medicine* 92 (2018) 188–196.
343 doi:10.1016/j.combiomed.2017.11.017.
- 344 [10] R. S. Oakes, T. J. Badger, E. G. Kholmovski, et al., Detection and quantifica-
345 tion of left atrial structural remodeling with delayed-enhancement magnetic
346 resonance imaging in patients with atrial fibrillation, *Circulation* 119 (13)
347 (2009) 1758–1767. doi:10.1161/CIRCULATIONAHA.108.811877.
- 348 [11] N. F. Marrouche, D. Wilber, G. Hindricks, et al., Association of atrial tis-
349 sue fibrosis identified by delayed enhancement MRI and atrial fibrillation
350 catheter ablation: the DECAAF study, *The Journal of the American Medical*
351 *Association* 311 (5) (2014) 498–506. doi:10.1001/jama.2014.3.
- 352 [12] E. M. Benito, A. Carlosena-Remirez, E. Guasch, et al., Left atrial fibro-
353 sis quantification by late gadolinium-enhanced magnetic resonance: a new
354 method to standardize the thresholds for reproducibility., *EP Europace* 19 (8)
355 (2017) 1272–1279. doi:10.1093/europace/euw219.
- 356 [13] J. Chen, T. Arentz, H. Cochet, et al., Extent and spatial distribution
357 of left atrial arrhythmogenic sites, late gadolinium enhancement at mag-

- netic resonance imaging, and low-voltage areas in patients with persistent atrial fibrillation: comparison of imaging vs. electrical parameters of fibrosis and arrhythmogenesis, *EP Europace* 21 (10) (2019) 1484–1493. doi:10.1093/europace/euz159.
- [14] A. S. Jadidi, H. Lehrmann, C. Keyl, et al., Ablation of persistent atrial fibrillation targeting low-voltage areas with selective activation characteristics, *Circulation. Arrhythmia and Electrophysiology* 9 (3). doi:10.1161/CIRCEP.115.002962.
- [15] D. Nairn, H. Lehrmann, B. Müller-Edenborn, et al., Comparison of unipolar and bipolar voltage mapping for localization of left atrial arrhythmogenic substrate in patients with atrial fibrillation, *Frontiers in Physiology* 11. doi:10.3389/fphys.2020.575846.
- [16] K. P. Anderson, R. Walker, P. Urie, et al., Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy., *Journal of Clinical Investigation* 92 (1) (1993) 122–140. doi:10.1172/JCI116540.
- [17] K. Higuchi, J. Cates, G. Gardner, et al., The spatial distribution of late gadolinium enhancement of left atrial magnetic resonance imaging in patients with atrial fibrillation, *JACC: Clinical Electrophysiology* 4 (1) (2018) 49–58. doi:10.1016/j.jacep.2017.07.016.
- [18] B. Müller-Edenborn, Z. Moreno-Weidmann, S. Venier, et al., Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. a multicenter observational study of the RETAC (reseau européen de traitement d’arrhythmies

- cardiaques)-group, *Clinical Research in Cardiology* doi:10.1007/s00392-021-01973-1.
- [19] N. F. Marrouche, T. Greene, J. M. Dean, et al., Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design, *Journal of Cardiovascular Electrophysiology* 32 (4) (2021) 916–924. doi:10.1111/jce.14957.
- [20] S. Rolf, S. Kircher, A. Arya, et al., Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation., *Circulation. Arrhythmia and electrophysiology* 7 (5) (2014) 825–33. doi:10.1161/CIRCEP.113.001251.
- [21] P. Müller, H. Makimoto, J. W. Dietrich, Others, Association of left atrial low-voltage area and thromboembolic risk in patients with atrial fibrillation, *EP Europace* 20 (2018) 359–365. doi:10.1093/europace/eux172.
- [22] Y. Huo, T. Gaspar, M. Pohl, et al., Prevalence and predictors of low voltage zones in the left atrium in patients with atrial fibrillation, *EP Europace* 20 (6) (2018) 956–962. doi:10.1093/europace/eux082.
- [23] B. Müller-Edenborn, J. Chen, J. Allgeier, et al., Amplified sinus-p-wave reveals localization and extent of left atrial low-voltage substrate: implications for arrhythmia freedom following pulmonary vein isolation., *EP Europace* doi:10.1093/europace/euz297.
- [24] G. Caixal, T. Althoff, P. Garre, et al., Proximity to the descending aorta predicts regional fibrosis in the adjacent left atrial wall: aetiopathogenic

- 402 and prognostic implications, *EP Europace* 23 (10) (2021) 1559–1567.
403 doi:10.1093/europace/euab107.
- 404 [25] B. J. Hansen, J. Zhao, V. V. Fedorov, Fibrosis and atrial fibrillation: Comput-
405 erized and optical mapping, *JACC: Clinical Electrophysiology* 3 (6) (2017)
406 531–546. doi:10.1016/j.jacep.2017.05.002.
- 407 [26] C. Nagel, G. Luongo, L. Azzolin, et al., Non-invasive and quantitative esti-
408 mation of left atrial fibrosis based on p waves of the 12-lead ECG-a large-
409 scale computational study covering anatomical variability., *Journal of Clinical*
410 *Medicine* 10 (8). doi:10.3390/jcm10081797.
- 411 [27] G. Luongo, L. Azzolin, S. Schuler, et al., Machine learning enables nonin-
412 vasive prediction of atrial fibrillation driver location and acute pulmonary
413 vein ablation success using the 12-lead ECG, *Cardiovascular Digital Health*
414 *Journal* 2 (2) (2021) 126–136. doi:10.1016/j.cvdhj.2021.03.002.
- 415 [28] S. Y. Ho, J. A. Cabrera, D. Sanchez-Quintana, Left atrial anatomy revis-
416 ited, *Circulation: Arrhythmia and Electrophysiology* 5 (1) (2012) 220–228.
417 doi:10.1161/CIRCEP.111.962720.